459 related articles for article (PubMed ID: 18245109)
1. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
2. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
[TBL] [Abstract][Full Text] [Related]
4. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
[TBL] [Abstract][Full Text] [Related]
5. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
6. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
Haraoui B; Cameron L; Ouellet M; White B
J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
[TBL] [Abstract][Full Text] [Related]
8. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
[TBL] [Abstract][Full Text] [Related]
9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
10. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
11. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
12. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
Stern R; Wolfe F
J Rheumatol; 2004 Aug; 31(8):1538-45. PubMed ID: 15290732
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
14. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
Vander Cruyssen B; Van Looy S; Wyns B; Westhovens R; Durez P; Van den Bosch F; Veys EM; Mielants H; De Clerck L; Peretz A; Malaise M; Verbruggen L; Vastesaeger N; Geldhof A; Boullart L; De Keyser F
Arthritis Res Ther; 2005; 7(5):R1063-71. PubMed ID: 16207323
[TBL] [Abstract][Full Text] [Related]
15. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
McGonagle D; Tan AL; Madden J; Taylor L; Emery P
Rheumatology (Oxford); 2008 Jun; 47(6):865-7. PubMed ID: 18390581
[TBL] [Abstract][Full Text] [Related]
16. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Geborek P; Saxne T
Rheumatology (Oxford); 2009 Mar; 48(3):243-5. PubMed ID: 19106164
[TBL] [Abstract][Full Text] [Related]
18. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
19. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
20. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
